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Stress management for mRNAs
A
n enzyme involved in mRNA degradation turns into a 
transcript stabilizer during stress, Yoon et al. report.
mRNA fates are determined by their association 
with regulatory proteins in ribonucleoprotein (mRNP) complexes. 
mRNPs can accumulate in large, cytosolic aggregates; P bodies, 
for example, contain translationally repressed mRNAs complexed 
with proteins that initiate mRNA destruction. One of these proteins 
is the enzyme Dcp2p, which removes the 5 cap from mRNAs to 
spur their degradation. Yoon et al. found that budding yeast Dcp2p 
is phosphorylated during cell stress, when cells alter the fate of 
many of their mRNAs to aid their survival and recovery.
Dcp2p was phosphorylated by the stress-activated kinase 
Ste20p. Blocking this modifi   cation—either by mutating the 
phosphorylation site or deleting the kinase—prevented Dcp2p 
from accumulating in P bodies during stress and inhibited the 
formation of a second type of RNA–protein aggregate called 
stress granules. Yeast stress granules can depend on P bodies 
for their formation and contain repressed mRNAs that may be 
poised to re-begin translation. A Dcp2p mutant mimicking the 
phosphorylated form accumulated normally in P bodies and 
restored stress granules to yeast lacking Ste20p.
The phosphomimetic form of Dcp2p also stabilized a subset of 
yeast mRNAs, including a number of transcripts encoding ribosomal 
proteins. Senior author Roy Parker thinks that Dcp2p phosphory-
lation changes the fate of these transcripts by altering the decapping 
enzyme’s interactions with other regulatory proteins, promoting the 
mRNAs’ stable accumulation in stress granules instead of initiating 
their degradation. The mRNAs are thus poised to be translated once 
conditions improve, allowing the yeast to rapidly recover.
Yoon, J.-H., et al. 2010. J. Cell Biol. doi:10.1083/jcb.200912019.
The story of O-glycosylation
T
he tyrosine ki-
nase Src boosts 
protein glyco-
sylation by stimulating 
the transport of specifi  c 
enzymes from the 
Golgi to the ER, Gill 
et al. reveal.
Src is activated 
downstream of growth factor receptors, but although a portion of 
the kinase localizes to the Golgi, little is known about its function 
at this organelle. Gill et al. discovered that growth factor stimulation 
induced a group of glycosylating enzymes called GalNac-Ts to 
relocate from the Golgi to the ER. This redistribution was blocked 
by inhibiting Src or by preventing the formation of COP-I transport 
vesicles. These vesicles only convey GalNac-Ts in response to Src 
activation: other glycosylation enzymes stayed put in the Golgi.
GalNac-Ts add N-acetylgalactosamine sugars to serine 
and threonine residues of secretory proteins—the initial step 
in the O-glycosylation pathway. Src activation and enzyme 
redistribution increased O-glycosylation levels, perhaps because 
ER-localized GalNac-Ts have access to their protein substrates 
for longer, or because they face less competition from other 
glycosylation enzymes that remain in the Golgi.
Senior author Frederic Bard now wants to understand how 
GalNac-Ts are specifi  cally recruited into COP-I vesicles upon Src 
activation—he suspects that the kinase phosphorylates an adaptor 
protein that links the enzymes to the COP-I machinery. Another 
question is how increased O-glycosylation affects cell behavior. 
One possibility is that changing the glycosylation pattern of cell 
surface proteins will alter their interactions with neighboring 
cells or the extracellular matrix, suggesting a potential new way 
for growth factors and Src to infl  uence cell adhesion.
Gill, D.J., et al. 2010. J. Cell Biol. doi:10.1083/jcb.201003055.
A marker recognizing O-glycosylated 
proteins (green) labels the Golgi (red) in 
unstimulated cells (left), but stains the ER 
after EGF treatment (right).
Nebulin doesn’t measure up
P
appas et al. dem-
onstrate that the 
giant disease-
related protein nebulin 
stabilizes actin fi  laments 
to control their length in 
skeletal muscle.
Nebulin is big 
enough to stretch the 
entire length of muscle 
thin filaments, binding individual actin subunits via a series 
of repeated domains. Alternative splicing produces nebulin 
molecules in various sizes that match the filament lengths 
of different muscle tissues, suggesting that nebulin acts as a 
“molecular ruler,” setting fi  lament length by binding a defi  ned 
number of actin monomers. The protein’s size has hampered 
efforts to test its function directly, so Pappas et al. synthesized a 
truncated “mini-nebulin” to replace the longer version.
Muscle cells expressing mini-nebulin contained fi  laments 
that were longer than mini-nebulin itself, indicating that the protein 
doesn’t measure out fi  lament length directly. Instead, nebulin 
regulates thin fi  lament size by stabilizing them: both full-length 
and mini-nebulin protected fi  laments from the depolymerizing 
drug latrunculin A. Filaments never depolymerized to lengths 
shorter than mini-nebulin, suggesting that the protein binds 
the fi  laments to set their minimum size. But photobleaching 
experiments revealed that mini-nebulin also stabilized fi  lament 
ends not directly bound by the protein, allowing the fi  laments to 
grow longer still.
Senior author Carol Gregorio now wants to investigate how 
mini-nebulin stabilizes parts of the actin fi  lament it has no contact 
with. The shortened protein will also enable studies of nebulin 
mutations that cause nemaline myopathy, a human disease 
characterized by protein aggregates and muscle weakness, and 
sometimes short, thin fi  laments.
Pappas, C.T., et al. 2010. J. Cell Biol. doi:10.1083/jcb.201001043.
Nebulin (red) stabilizes actin ﬁ  laments (green) 
to protect them from latrunculin A. In the 
protein’s absence (right), the depolymerizing 
drug causes ﬁ  lament disassembly.